MediPrint Lens (Dry Eye)
Dry Eye Disease
Pre-clinical/ResearchActive
Key Facts
About MediPrint Ophthalmics
MediPrint Ophthalmics is a private, clinical-stage biotech company addressing significant unmet needs in ophthalmology through its proprietary MediPrint™ contact lens drug delivery platform. The company has completed a Phase 2a study and is advancing its lead glaucoma program into Phase 2b, with a pipeline targeting multi-billion dollar markets. With a clear path to Phase 3 data and a focus on non-invasive, patient-friendly therapies, MediPrint aims to establish a new standard of care in ocular drug delivery.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| CEQUA (cyclosporine) | Sun Pharmaceutical | Approved |
| DE-120 (Ciclosporin ophthalmic gel) | Rohto Pharmaceutical | Phase 3 |
| DE-130 (Eicosapentaenoic Acid Ethyl Ester) | Santen Pharmaceutical | Phase 3 |
| DE-126 (SIP Receptor Modulator) | Santen Pharmaceutical | Phase 2 |
| DE-127 | Santen Pharmaceutical | Phase 1 |
| OTX-CSI (cyclosporine insert) | Ocular Therapeutix | Phase 3 |
| voclosporin | Aurinia Pharmaceuticals | Phase 2/3 |
| HROW-324 (SHP-659) | Harrow Health | Phase 2 |
| PL9643 (Melody-1) | Palatin Technologies | Phase 3 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |